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Abstract
Background/Objective: Metastatic adenocarcinoma from an unknown primary site is a common clinical problem.
Determining the cytokeratin (CK) 7/CK20 pattern of tumors is one of the most helpful procedures for this purpose
since the CK7-/CK20+ pattern is typical of colorectal adenocarcinomas. CDX2, a critical nuclear transcription factor
for intestinal development, is expressed in intestinal epithelium and adenocarcinomas. In the present study, we
compared the sensitivity and specificity of CDX2 expression and the CK7-/CK20+ phenotype in differentiating
colorectal adenocarcinomas from pancreatic and gastric adenocarcinomas.
Methods: CK7/CK20 staining pattern and CDX2 expression were evaluated in 118 cases of colorectal, 59 cases of
gastric, and 32 cases of pancreatic adenocarcinomas. The sensitivity, specificity, and positive and negative
predictive values of the CK7-/CK20+ phenotype and of CDX2 expression were analyzed.
Results: The CK7-/CK20+ immunophenotype was expressed by 75 of 118 (64%) colorectal and 3 of 59 (5%) gastric
tumors and was not observed in any pancreatic adenocarcinomas. The CK7+/CK20+ immunophenotype was
expressed in 24/118 (20%) of colon, 28/59 (48%) of gastric and 7/32 (22%) of pancreatic adenocarcinomas. The CK7
+/CK20- expression pattern was observed in only 2% (2 of 118) of colorectal carcinomas. CDX2 was expressed in
114 of 118 (97%) colorectal, 36 of 59 (61%) gastric, and 5 of 32(16%) pancreatic adenocarcinomas. There was no
significant association between CDX2 expression and tumor differentiation in colorectal carcinomas. In gastric
carcinomas, CDX2 expression was more common in intestinal type tumors than in diffuse type carcinomas. The
CK7-/CK20+ phenotype showed a specificity of 96.7% in predicting colorectal adenocarcinomas, which was
superior to that of CDX2 expression. CDX2 expression at both cut-off levels (> 5% and > 50%) had a higher
sensitivity (96.6% and 78%) than the CK phenotype.
Conclusions: Both the CK7-/CK20+ phenotype and expression of the antibody CDX2 are highly specific and
sensitive markers of colorectal origin. CDX2 expression should be a useful adjunct for the diagnosis of intestinal
adenocarcinomas, particularly when better established markers such as CK7 and CK20 yield equivocal results. The
CK7-/CK20+ phenotype is superior in its specificity and positive predictive value and might be preferred.
Virtual slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/4851011866354821
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Metastatic adenocarcinoma from an unknown primary
site is a common clinical problem that leads to extensive
and costly clinical and radiological examinations, some-
times with discouraging results [1,2]. It is often impor-
tant to determine the site of origin of a metastatic
carcinoma of unknown primary site, particularly because
this may affect the choice of the treatment. A more pre-
cise diagnosis leads to more effective treatment, substan-
tially improving the overall outcome [3]. Determination
of the primary site may take several steps. Clinical fea-
tures, such as age, sex, and site of metastases may give a
first indication. The histological assessment is often very
helpful, but may not differentiate adequately between
various primary tumors. Immunohistochemistry is the
most common adjunctive method used in the analysis of
the patient with cancer of unknown primary site [4,5].
Cytokeratins (CKs) represent the epithelial class of inter-
mediate-sized filaments of the cytoskeleton. There are 20
subtypes of cytokeratin (CK) intermediate filaments.
These have different molecular weights and demonstrate
differential expression in various cell types and tumors [6].
Among the most useful cytokeratins are CK7 and CK20
[7]. CK7 is found in many ductal and glandular epithelia,
including lung, breast, ovary, and endometrium [8,9].
CK20 is expressed in the gastrointestinal (GI) epithelium,
urothelium, and Merkel cells [10]. The combined expres-
sion patterns of CK7 and CK20 have been extensively stu-
died in various primary and metastatic carcinomas
[5,7,11-17]. CK20 is expressed alone in the majority of
intestinal adenocarcinoma and in Merkel cell carcinomas
whereas CK7 is present without CK20 in most breast, lung
and ovarian adenocarcinoma, and with CK20 in urothelial,
pancreatic and gastric carcinomas. The CK7-/CK20+
expression pattern is known to be highly characteristic of
colorectal carcinomas [11,12,17-19], however, not all col-
orectal carcinomas show the CK7-/CK20+ expression pat-
tern. Occasionally colorectal carcinomas may show
significant CK7 expression and conversely, expression of
CK20 may be seen in a variety of non-colorectal adenocar-
cinomas such as urothelial, gastric and pancreatobiliary
tract carcinomas [20-24]. For this reason, there is contin-
ued interest in the development of new and more specific
markers of intestinal differentiation and CDX2 appears to
be such a marker.
CDX2 is a caudal-type homeobox gene, encoding a
transcription factor that plays an important role in pro-
liferation and differentiation of intestinal epithelial cells
[25]. The protein (CDX2) is normally expressed
throughout embryonic and postnatal life within nuclei
of intestinal epithelial cells from the proximal duode-
num to the distal rectum [26,27]. Previous studies
showed that CDX2 is expressed in normal and
neoplastic intestinal epithelial cells with a relatively high
sensitivity and specificity and that it can be used as an
immunohistochemical marker for neoplasms of intest-
inal origin [28-32]. However, CDX2 expression was also
found in gastric carcinoma, and other carcinomas with
intestinal-type morphology [33-36].
In the present study, we examined the expression pro-
files of CK7, CK20, and CDX2 immunohistochemical
markers in primary colorectal, gastric and pancreatic
adenocarcinomas in consideration of the potential
applicability of these markers in the clinical context of
metastatic adenocarcinomas. We also evaluated the sen-
sitivity, specificity, positive predictive value, and negative
predictive value of CDX2 expression and CK7-/CK20+
immunophenotype to differentiate colorectal adenocarci-
nomas from pancreatic and gastric adenocarcinomas.
Materials and methods
Case selection and tissue samples
One hundred eighteen colorectal, 59 gastric and 32 pan-
creatic adenocarcinoma resection specimens were
retrieved from the archival files of the Department of
Pathology, Fatih University Medical School, between Jan-
uary 2006 and December 2009. Pathological findings,
including histological type, histological differentiation,
depth of invasion, and lymph node status, were gathered
from hematoxylin and eosin stained sections. All cases
were reviewed to confirm the diagnosis. The grade and
histological type of colorectal and pancreatic adenocarci-
nomas were determined according to criteria of the
World Health Organization (WHO) Classification of
Tumors [37]. Well and moderately differentiated tumors
were grouped together as low-grade tumors and were
compared with high-grade tumors, which included
poorly differentiated and undifferentiated tumors, and
signet ring cell carcinomas. Histological typing of gastric
carcinomas was made according to Lauren classification
[38]. Adenocarcinomas of intestinal type, which were
well or moderately differentiated, were recorded as low
grade tumors, whereas the poorly differentiated intestinal
type adenocarcinomas and the diffuse type adenocarcino-
mas were recorded as high grade tumors. Postoperative
pathological staging was performed according to the
American Joint Committee on Cancer (AJCC) TNM sta-
ging system [39]. One paraffin block with the maximum
amount of tumor and proper fixation was selected from
each case for immunohistochemical studies. This study
was approved by Ethics Committee of Fatih University
Hospital (09.23.2010/B 302 FTH 0200000)
Immunohistochemical Analysis
Four μm-thick sections were cut from blocks of paraffin
embedded tissue, deparaffinized, and rehydrated as
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to endogenous peroxidase, slides were incubated in
Hydrogen Peroxide Block for 15 min. Before immunos-
taining, antigen retrieval was performed by incubating
the slides for 15 min with pepsin (LabVision; catalog no.
AP-9007) at a concentration of 1mg/ml for CK20. Slides
were microwaved in 10 mM of citric acid at pH6.0 for
20 min for CK7 and CDX2. The slides were incubated
for 60 min with primary antibodies to CK7 (clone OV-
TL 12/30, LabVision/NeoMarkers; 1:50), CK20 (clone
Ks20.8, Dako; 1:50) and CDX2 (clone AMT 28, Novo-
Castra; 1:50) at room temperature. The Standard avidin-
biotin-peroxidase complex (ABC) technique was per-
formed using the LabVision Secondary Detection Kit
(UltraVision Detection System Anti-polyvalent, HRP).
AEC was used as chromogen. All slides were counter
stained with Mayer’s hematoxylin.
Microscopic Evaluation
For CDX2, only nuclear staining was considered posi-
tive. Cytoplasmic positivity was infrequently encoun-
tered, and was considered an artifact. Positive
immunostaining for CK7 and CK20 was identified in the
cytoplasm, cell membrane, or both. The percentage of
positive cells was scored in a semiquantitative method
according to the following scheme: 0 (less than 5% of
tumor cells); 1+ (positive signal of any intensity in 5-
25% of tumor cells); 2+ (26-50% of tumor cells); 3+ (51-
75% of tumor cells); and 4+ (greater than 75% of tumor
cells). Furthermore, staining in less than 50% of the
tumor cells was considered focal, and staining in more
than 50% of the tumor cells was considered diffuse posi-
tivity. In general, cases showing 3+ and 4+ staining also
had strong intense staining, so intensity was not used in
determination of the final reactivity score. Normal colo-
nic mucosal tissue was used as a CK20 and CDX2-posi-
tive control, and normal pancreatic tissue was used as a
CK7-positive control. For negative control samples, the
primary antibody was omitted for each run.
Statistical analysis
c
2and Fisher exact tests were used to compare the dif-
ferences in percentages of positive results between
groups. SPSS 13.0 for Windows was used for all statisti-
cal analyses. The sensitivity, specificity, and positive and
negative predictive values of the CK7-/CK20+ phenotype
and of CDX2 expression were counted.
Results
Tables 1 and 2 show the percentage of cases that
stained with CDX2, CK7, and CK20 in colorectal adeno-
carcinomas, gastric adenocarcinomas and pancreatic
adenocarcinomas.
CK7 and CK20
CK7 expression was detected in 22% (26/118) of color-
ectal, in 80% (47/59) of gastric, and in 97% (31/32) of
pancreatic adenocarcinomas. CK20 reactivity was found
in 84% (99/118) of colorectal, in 53% (31/59) of gastric,
and in 22% (7/32) of pancreatic adenocarcinomas. The
CK7-/CK20+ immunophenotype was expressed by 75 of
118 (64%) colorectal and 3 of 59 (5%) gastric tumors
and was not observed in any pancreatic adenocarcino-
mas (c
2 = 79.992; p < 0.001). The CK7+/CK20+ immu-
nophenotype was expressed in 24/118 (20%) of colon,
28/59 (48%) of gastric and 7/32 (22%) of pancreatic ade-
nocarcinomas, which was not helpful in the differential
diagnosis. However, among the CK20 positive cases,
CK20 reactivity was diffuse (more than 50% of cells
were positive) in the majority of colorectal carcinomas
in 64% (63/99) of the cases and mainly focal ( < 50% of
cells were positive) in gastric and pancreatic adenocarci-
nomas in 71% (22/31) and 100% (7/7) of cases respec-
tively (c
2 = 19.509; p < 0.001) (Figure 1). Conversely,
among the CK7 positive cases, CK7 reactivity was dif-
fuse in the majority of gastric and pancreatic adenocar-
cinomas in 74% (35/47) and 94% (29/31) of cases
respectively, and this reactivity was focal in 54% (14/26)
of colorectal carcinomas (c
2 = 16.228;p < 0.001) (Figure
Table 1 Distribution of CK7, CK20 and CDX2 staining with percentages of positive cells in primary colorectal, gastric
and pancreatic adenocarcinomas
Negative Positive Total
0 1 +2 +3 +4 +
Colorectal adenocarcinoma CK7 92 (78%) 8 (7%) 6 (5%) 5 (4%) 7 (6%) 118
CK20 19 (16%) 20 (17%) 16 (13%) 22 (19%) 41 (35%) 118
CDX2 4 (3%) 7 (6%) 15 (13%) 21 (18%) 71 (60%) 118
Gastric adenocarcinoma CK7 12 (20%) 5 (9%) 7 (12%) 6 (10%) 29 (49%) 59
CK20 28 (47%) 16 (27%) 6 (10%) 8 (14%) 1 (2%) 59
CDX2 23 (39%) 13 (22%) 9 (15%) 10 (17%) 4 (7%) 59
Pancreatic adenocarcinoma CK7 1 (3%) 1 (3%) 1 (3%) 9 (28%) 20 (63%) 32
CK20 25 (78%) 6 (20%) 1 (3%) 0 (0%) 0 (0%) 32
CDX2 27 (85%) 3 (9%) 2 (6%) 0 (0%) 0 (0%) 32
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only 2% (2 of118) of colorectal carcinomas, although it
was expressed in 32% (19/59) of gastric and 75% (24/32)
of pancreatic adenocarcinomas (c
2 = 85.607; p < 0.001).
In our study, 17(14%) colorectal, 9 (15%) gastric, and
only 1 (3%) pancreatic adenocarcinomas showed a
CK7-/CK20- immunophenotype.
CK7 and CK20 expression were compared with the
clinicopathological characteristics of the tumors (Table
3). No association between CK7 expression and anatomi-
cal location of carcinomas, tumor type, stage, and grade
was found. No association was observed among CK20
expression and tumor type, tumor stage (pT), or nodal
status. Among the colorectal tumors, CK20 positivity was
more common in rectal carcinomas than in nonrectal
colon carcinomas (89% versus 70%, c
2 = 6.839; p = 0.009)
and in low grade carcinomas than in high grade carcino-
mas (91% versus 55%, c
2 = 17,247; p < 0.001).
Table 2 CK7/20 phenotype and CDX2 expression in our studied groups
Colorectal AdenoCa
(n = 118)
Gastric AdenoCa
(n = 59)
Pancreatic AdenoCa
(n = 32)
CDX2+ CDX2- CDX2+ CDX2- CDX2+ CDX2-
CK7-/CK20+ 74 (62%) 1 (1%) 3 (5%) 0 (0%) 0 (0%) 0 (0%)
CK7+/CK20+ 22 (19%) 2 (2%) 21 (36%) 7 (12%) 2 (6%) 5 (16%)
CK7+/CK20- 2 (2%) 0 (0%) 8 (14%) 11 (19%) 3 (9%) 21 (66%)
CK7-/CK20- 16 (14%) 1 (1%) 4 (7%) 5 (9%) 0 (0%) 1 (3%)
A 
A B 
 
C 
Figure 1 CK20 staining in colorectal, gastric, and pancreatic adenocarcinomas. (A) Colorectal adenocarcinoma displayed diffuse and strong
immunoreactivity in the cytoplasm of cancer cells. (B) Gastric and (C) pancreatic adenocarcinomas exhibited focal cytoplasmic staining for CK20.
Original magnification × 100.
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CDX2 was expressed in 114 of 118 (97%) colorectal, 36
of 59 (61%) gastric, and 5 of 32 (16%) pancreatic adeno-
carcinomas (c
2 = 93.576; p < 0.001). In positive cases,
the immunoreactivity was predominantly nuclear with
occasional faint cytoplasmic staining. The majority of
cases (92/114, 81%) demonstrated strong and diffuse
immunostaining in more than 50% of cells in colorectal
tumors. Among the CDX2 positive gastric carcinomas
(36/59), reactivity was focal in 22 cases (22/36, 61%).
Among the 32 cases of pancreatic adenocarcinoma, only
5 cases were focally positive for CDX2 (c
2 = 33.462; p <
0.001) (Figure 3).
CDX2 expression was also compared with the clinico-
pathological characteristics of the tumors (Table 3). In
gastric carcinomas CDX2 expression was more common
in intestinal type tumors than in diffuse type carcinomas
(77% versus 45%, c
2 = 6.284; p = 0.012). There was no
significant association between CDX2 expression and
tumor differentiation in colorectal carcinomas (98% of
low grade tumors and 91% of high grade tumors were
positive for CDX2) (Figure 4). Conversely, among gastric
carcinomas CDX2 positivity was more common in low
grade carcinomas than in high grade carcinomas (80%
versus 51%, c
2 = 4.584; p = 0.032). No association was
observed among CDX2 expression and anatomical loca-
tion of carcinomas, tumor stage (pT), or nodal status.
Comparison of CK7/20 staining pattern and CDX2
expression
The CK7-/CK20+/CDX2+ phenotype was highest,
accounting for 63% (74/118) of colorectal adenocarcino-
mas. In gastric and pancreatic adenocarcinomas, CK7
+/CK20+/CDX2+ (21/59, 36%) and CK7+/CK20-/
CDX2- (21/32, 66%) were the most common patterns
respectively. In CK7+/CK20+ tumors, CDX2 expression
was observed in 22 of 24 (92%) colorectal, 21 of 28
(75%) gastric, and 2 of 7 (29%) pancreatic carcinomas.
A 
 
B 
C 
Figure 2 CK7 immunostaining in colonic, gastric, and pancreatic tumors. (A) Gastric and (B) pancreatic carcinomas showed diffuse and
strong positive CK7 immunostaining. (C) Colonic adenocarcinoma displayed focal cytoplasmic immunoreactivity for CK7. (A)-(B), original
magnification × 100; (C), original magnification × 200.
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cinomas in 68% (15/22) of the cases and mainly focal in
gastric and pancreatic adenocarcinomas in 57% (12/21)
and 100% (2/2) of cases respectively (c
2 = 5.979; p =
0.051). Among the CK7-/CK20- colorectal tumors
CDX2 was positive in 16 of 17 (94%) cases.
We also evaluated the sensitivity, specificity, positive
predictive value, and negative predictive value of
CDX2 expression and CK7-/CK20+ immunophenotype
to differentiate colorectal adenocarcinoma from pan-
creatic and gastric adenocarcinomas (Table 4). Deter-
mining the CK7/CK20 phenotype proved to be more
specific in differentiating colorectal adenocarcinoma
from pancreatic and gastric adenocarcinomas (specifi-
city 96.7%) than the expression of CDX2 was. The
CK7-/CK20+ phenotype had a superior positive predic-
tive value (96.2%) in these circumstances. CDX2
expression at both cut-off levels (> 5% and > 50%) had
a higher sensitivity (96.6% and 78%) and higher nega-
tive predictive value (92.6% and 74.8%) than the CK
phenotype. The specificity of CDX2 expression did not
reach the level of specificity of CK7/CK20 phenotype
at a > 50% level, either (84.6%).
Discussion
The diagnosis of the metastatic carcinoma of unknown
origin can be very difficult. The determination of the
primary site of the metastasis is a challenge to both
oncologists and pathologists, having potentially impor-
tant clinical and therapeutic consequences [1-3]. In the
setting of carcinomas of unknown primary, clinicopatho-
logical correlation and a panel of standard immunos-
tains help define the primary site, and direct appropriate
treatment [4,5].
Cytokeratins are group of approximately 20 proteins
that consist of a type of intermediate filament and are
differentially expressed in epithelia of various sites. The
cytokeratins most often used are CK7 and CK20 [7-10].
CK7 is found in the glandular epithelium and epithelial
tumors of lung, ovary, endometrium and breast, but is
not found in GI epithelium. Conversely, CK20 is
expressed principally in the normal glands and epithelial
tumors of the GI tract, urothelium, and Merkel cells.
The cytokeratin 7/20 profile of a particular tumor has
proved to be a useful aid in differential diagnosis of car-
cinomas, since primary and metastatic tumors tend to
retain the cytokeratin profiles of the epithelium from
which they arise [13]. In his review article, Tot summar-
ized the results of 29 studies containing more than 3500
reported cases of adenocarcinomas stained with CK20
and CK7. This review stated that metastatic colorectal,
gastric and pancreatic adenocarcinomas have similar
CK7 and CK20 staining ratios as their respective pri-
mary tumors. Only gastric adenocarcinomas showed sta-
tistically significant differences in CK20 expression when
the primary and metastatic locations were compared
[13].
Normal epithelium of the small bowel, appendix and
colorectum, and adenocarcinomas from these sites, are
almost consistently CK7-/CK20+, helping to distinguish
these adenocarcinomas from adenocarcinomas of many
other primary sites [9-15]. The CK7-/CK20+ pattern
was identified in 65% to 95% of the colorectal adenocar-
cinomas in different series [11,12,20-23,31]. On the
other hand approximately one third of gastric and less
than 10% of pancreatic adenocarcinomas also show this
pattern [11,12,23]. The CK7-/CK20+ immunophenotype
was expressed by 75 of 118 (64%) colorectal and 3 of 59
(5%) gastric tumors and was not observed in any pan-
creatic adenocarcinomas in the present study. Therefore,
it has been presumed that CK7 is not typically expressed
by colonic epithelial tumors. Interestingly, several
reports have described CK7 expression in colorectal
adenocarcinoma, with expression ranging from 5% to
Table 3 Expression of CK7, CK20, and CDX2 in cancer tissues by histopathological characteristics
CK7+ CK20+ CDX2+
n%n%n%
Colorectal adenocarcinoma (n = 118)
Low grade (n = 96) 22 22.9 87 90.6 * 94 97.9
High grade (n = 22) 4 18.2 12 54.5 * 20 90.9
Rectal (n = 85) 18 21.2 76 89.4§ 83 97.6
Nonrectal (n = 33) 8 24.2 23 69.7§ 31 93.9
Gastric adenocarcinoma (n = 59)
Intestinal type (n = 30) 21 70.0 16 53.3 23 76.7 #
Diffuse type (n = 29) 26 89.7 15 51.7 13 44.8 #
Pancreatic adenocarcinoma (n = 32)
Low grade (n = 30) 30 100.0 7 23.3 5 16.7
High grade (n = 2) 1 50.0 0 0.0 0 0.0
* p < 0.001 § p = 0.009 # p = 0.012
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are unclear. However, this may be the result of differ-
ences in the studied population or the interpretive cri-
teria that was used. In our study, CK7 expression was
detected in 22% (26/118) of colorectal adenocarcinomas.
In comparison with the CK7-/CK20+ immunoprofile,
the CK7+/CK20+ immunoprofile is commonly present
A B 
C 
Figure 3 CDX2 expression patterns in colorectal, gastric, and pancreatic carcinomas. (A) Homogeneous (diffuse and strong) nuclear
expression of CDX2 in a low grade colorectal adenocarcinoma. (B) Gastric and (C) pancreatic adenocarcinomas showed heterogeneous pattern
of intensity of CDX2 expression, frequently encountered in extra-intestinal GI adenocarcinomas. (A)-(B), original magnification × 200; (C), original
magnification × 400.
Figure 4 CDX2 expression in a high grade colorectal
adenocarcinoma. Diffuse moderate to strong nuclear staining was
seen. Original magnification × 200.
Table 4 Sensitivity, specificity, and positive/negative
predictive values of CDX2 expression and CK7-/CK20+
immunophenotype in differentiating colorectal
adenocarcinomas from pancreatic and gastric
adenocarcinomas.
Sensitivity Specificity PPV NPV
CK7-/CK20+ 63.6% 96.7% 96.2% 67.2%
CDX2 > 5% 96.6% 54.9% 73.5% 92.6%
CDX2 > 50% 78.0% 84.6% 86.8% 74.8%
PPV: Positive Predictive Value NPV: Negative Predictive Value
Bayrak et al. Diagnostic Pathology 2012, 7:9
http://www.diagnosticpathology.org/content/7/1/9
Page 7 of 11in urothelial carcinomas, gastric carcinomas and tumors
of the pancreatobiliary tract [11,12,15]. Gastric adeno-
carcinomas are the most heterogeneous subgroup of
carcinomas with respect to their CK7/CK20 immuno-
phenotype. While most gastric adenocarcinomas are
CK20+, they may or may not be CK7+ [11,12,23]. The
results of CK7/CK20 immunohistochemistry for cholan-
giocarcinomas, gall bladder carcinoma and pancreatic
ductal adenocarcinoma are conflicting. While all studies
have found CK7 immunopositivity in these tumours,
many studies have found the majority are CK20-
[40,41], while others have found the majority to be
CK20+ [11,12]. In the present study the largest propor-
tion of gastric carcinomas was of the CK7+/CK20+ phe-
notype (48%), and a substantial proportion was of the
CK7+/CK20- phenotype (32%). CK7+/CK20- immuno-
profile was the most common pattern, accounting for
75% of pancreatic adenocarcinomas. The CK7+/CK20+
immunophenotype was expressed in 20% of colon, 48%
of gastric and 22% of pancreatic adenocarcinomas,
which was not helpful in the differential diagnosis. How-
ever, CK20 reactivity was diffuse (more than 50% of cells
were positive) in the majority of colorectal carcinoma
cases and mainly focal ( < 50% ofcells were positive) in
gastric and pancreatic adenocarcinomas as in previous
studies [22,23,31,41].
Since, occasional colorectal carcinomas may show sig-
nificant CK7 expression and conversely, expression of
CK20 may be seen in a variety of non-colorectal adeno-
carcinomas, there is interest in the development of new
and more specific markers of intestinal differentiation.
Human CDX2 protein is a member of the homeobox
genes that encodes an intestine-specific transcription
factor. This protein regulates intestinal development and
is expressed in the nuclei of epithelial cells throughout
the intestinal tract in embryonic and postnatal life
[25-27]. Expression of CDX2 mRNA has been shown to
be highly restricted to intestinal epithelium [42]. The
sensitivity and specificity of antibodies to CDX2 protein
as a marker of colonic adenocarcinoma has been
recently evaluated in various studies with reported sensi-
tivity and specificity of greater than 90% [28-33]. Wer-
l i n ge ta l[ 2 8 ]e x a m i n e dC D X 2e x p r e s s i o na c r o s s4 7 6
samples of human tumors and concluded that it is an
excellent marker of adenocarcinomas arising in the GI
tract, particularly the duodenum and colon. These
authors reported that high levels (> 75% positive cells)
of CDX2 expression were found almost exclusively in
adenocarcinomas of the colorectum, and intermediate
levels (26%-75% positive cells) of immunostaining were
found in many adenocarcinomas arising elsewhere in
the GI tract. They also demonstrated that primary and
metastatic colorectal carcinomas showed remarkably
similar scoring patterns. All primary and 25 of 26
metastatic colonic adenocarcinomas showed high levels
of CDX2 expression (2+ or 3+) in this study. In another
study, Kaimaktchiev et al [32] observed a greater than
80% concordance for CDX2 expression in the analysis
of matched primary and lymph node metastases. In
addition, all 17 colorectal metastases examined by whole
sections were CDX2 positive in this study. Using tissue
m i c r o a r r a y s ,M o s k a l u ke ta l[ 2 9 ]a n a l y z e dC D X 2s t a i n -
ing in 745 samples of human cancer and arrived at simi-
lar conclusions. Barbareschi et al [30] compared CDX2
expression in primary and metastatic tumors found in
the lung and concluded that this marker is highly selec-
tive for tumors originating from the colon and rectum,
but also stains metastases from the stomach and ovary.
In our study, CDX2 was expressed in 114 of 118 (97%)
colorectal, 36 of 59 (61%) gastric, and 5 of 32(16%) pan-
creatic adenocarcinomas. The majority of cases (92/114,
81%) demonstrated strong and diffuse immunostaining
in more than 50% of cells in colorectal tumors. Among
the CDX2 positive gastric carcinomas (36/59), reactivity
was focal in 22 cases (22/36, 61%). Among the 32 cases
of pancreatic adenocarcinoma, only 5 cases were focally
positive for CDX2.
Among colorectal adenocarcinomas, the relationship
between tumor grade and CDX2 staining has been con-
troversial. Hinoi et al [43] demonstrated that a rare sub-
set of poorly differentiated colonic carcinomas termed
large cell minimally differentiated carcinoma or medul-
lary carcinoma are characterized by microsatellite
instability and loss of CDX2 expression. Kaimaktchiev et
al [32] recently studied tissue microarray samples of
1109 colorectal adenocarcinomas and found a lack of
CDX2 reactivity in 14 (28%) of 50 poorly differentiated
tumors. They concluded that CDX2 expression
decreases with tumor differentiation. Other series, how-
ever, failed to find a strong correlation between CDX2
expression and the level of differentiation in colorectal
adenocarcinomas. In the study of Werling et al [28], 74
of 75 colonic carcinomas showed high levels of CDX2
expression (2+ or 3+). Although several high-grade
tumors showed scores of 2+ (26%-75% positive cells)
compared with scores of 3+ (> 75% positive cells) that
were observed in all well-differentiated carcinomas, the
authors concluded that the expression of CDX2 did not
appear to correlate with the level of tumor differentia-
tion. Saad et al [31] also showed that CDX2 expression
was not influenced by tumor grade. In this study, there
was no significant association between CDX2 expression
and tumor differentiation in colorectal carcinomas (98%
of low grade tumors and 91% of high grade tumors
were positive for CDX2). Our semiquantitative scoring
system did not, however, take into account the intensity
of immunostaining, but focused exclusively on the frac-
tion of cells positively immunostained. It is likely that
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expression might show differences related to tumor
differentiation.
CDX2 represents the latest in a series of transcription
factors that have found important applications in diag-
nostic surgical pathology as highly specific and sensitive
markers of specific cell and tumor types. Nuclear tran-
scription factors have several distinct advantages over
cytoplasmic ‘’differentiation’’ markers: (1) transcription
factors generally yield an ‘’all or none’’ signal, with most
of the positive cases containing positive signal in > 90%
of the tumor cell population; (2) given the nuclear loca-
lization of the signal, it is much less likely to be con-
fused with biotin or other sources of false positive
cytoplasmic signals; and (3) lack of association between
the levels of expression of nuclear transcription factors
and the state of differentiation of the tumor [28]. For
example, in the study described here, 114 of 118 cases
of colonic adenocarcinoma were CDX2-positive, inde-
pendent of tumor grade.
Expression of CDX2 in tumors other than colorectal
carcinoma has been previously reported
[28,29,32-35,40,41]. CDX2 expression has been docu-
mented in gastric adenocarcinoma by several different
groups [28,32,43-46]. Werling et al [28] reported scores
of 2+ (26%-75% positive cells) and 3+ (> 75% positive
cells) positivity in 17 (70%) of 24 cases. These authors
also reported that no association between any histologi-
cal subtypes within pancreatic or gastric tumors and
CDX2 expression could be discerned. In the study of
Kaimaktchiev et al [32], CDX2 staining was observed in
gastric adenocarcinomas (16 of 71), more commonly in
the intestinal-type than in the diffuse-type (28.9 vs
11.5%). Our results are entirely consistent with these
studies in that CDX2 staining was observed in 61% of
gastric adenocarcinomas and significantly favored in the
intestinal-type tumors over the diffuse variants (77%
versus 45%). Park et al [44] reported that, CDX2 expres-
sion was decreased in early gastric cancers, when com-
pared with dysplasia, and was even more reduced in
advanced cancers. Similarly, Kim et al [45] reported les-
ser CDX2 expression in early gastric cancers compared
to advanced tumors. Liu et al [46] also showed that
CDX2 expression is progressively decreased in gastric
intestinal metaplasia, dysplasia, and cancer. We didn’t
find any association between CDX2 expression and
stage of gastric adenocarcinomas. As for CDX2 expres-
sion in pancreatic ductal adenocarcinomas, there
appears to be somewhat less agreement in the literature.
Werling et al [28] reported scores of 2+ (26%-75% posi-
tive cells) and 3+ (> 75% positive cells) positivity in 7
(32%) of 22 cases, Moskaluk et al [29] found 1+ ( <
25% positive cells) expression in 8 (33%) of 24 cases,
and in the series of Chu et al [35], CDX2 reacted with
10 (22%) of 46 cases. In contrast, Kaimaktchiev et al
[32] found that only 3 of 70 cases were positive for this
marker. In the present study, among the 32 cases of
pancreatic adenocarcinomas, only 5 cases were focally
positive for CDX2.
Based on the studies mentioned above CDX2 expression
alone does not reliably distinguish between colorectal ade-
nocarcinomas and adenocarcinomas arising elsewhere in
the GI tract, particularly pancreatobiliary and gastric ade-
nocarcinomas, although the sensitivityof CDX2 for color-
ectal cancer is significantly higher than for these latter
tumors. Qualitatively, focal and weak CDX2 expression in
a given tumor favors extra-intestinal origin whereas uni-
form intense expression favors intestinal origin. In com-
parison with the CK7-/CK20+ immunoprofile Tot [47]
found that CK7-/CK20+ expression pattern was more spe-
cific for colonic adenocarcinoma metastases than CDX2
alone (98.7% vs 90%), but less sensitive (79.5% vs. 84%).
We also evaluated the sensitivity, specificity, positive pre-
dictive value, and negative predictive value of CDX2
expression and CK7-/CK20+ immunophenotype to differ-
entiate colorectal adenocarcinoma from pancreatic and
gastric adenocarcinomas. Determining the CK7/CK20
p h e n o t y p ep r o v e dt ob em o r es p e c i f i ci nd i f f e r e n t i a t i n g
colorectal adenocarcinoma from pancreatic and gastric
adenocarcinomas (specificity 96.7%) than the expression of
CDX2 was. The CK7-/CK20+ phenotype had a superior
positive predictive value (96.2%) in these circumstances.
CDX2 expression at both cut-off levels (> 5% and > 50%)
had a higher sensitivity (96.6% and 78%) and higher nega-
tive predictive value (92.6% and 74.8%) than the CK phe-
notype. The specificity of CDX2 expression did not reach
the level of specificity of CK7/CK20 phenotype at a > 50%
level, either (84.6%).
Conclusions
Both the CK7-/CK20+ phenotype and expression of the
antibody CDX2 are highly specific and sensitive markers
of colorectal origin. CDX2 expression should be a useful
adjunct for the diagnosis of intestinal adenocarcinomas,
especially those with CK7+/CK20+ or CK7-/CK20- pro-
files. The CK7-/CK20+ immunophenotype is more spe-
cific in differentiating colorectal adenocarcinomas from
pancreatic and gastric adenocarcinomas than CDX2
expression. The CK7-/CK20+ phenotype is superior in
its specificity and positive predictive value and might be
preferred.
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